Auvelity is an antidepressant medicine used to treat Major Depressive Disorder (MDD) which is a specific type of depression. Auvelity is a rapid-acting antidepressant that started working as early as 1 week, and patients’ depression symptoms continued to improve over time when compared to placebo in a 6-week clinical study for MDD (Study 1, NCT04019704).

Auvelity contains two active ingredients, bupropion and dextromethorphan. Auvelity is thought to work by increasing the amount of glutamate (a chemical messenger) available in your brain, which may positively affect your mood and ease depressive symptoms. It may also weakly affect your brain’s other neurotransmitters, norepinephrine and dopamine.

Auvelity became an FDA-approved medicine on August 18, 2022, for adults with major depressive disorder (MDD).

resource-Jama 0ctober 22/29 2024